Eton Pharmaceuticals vs Gyre Therapeutics
Gyre Therapeutics is the larger business, with $117m of revenue in fiscal 2025 against $80.0m for Eton Pharmaceuticals (1.5 times as much). Eton Pharmaceuticals grew faster (104.9% against 10.2%). Gyre Therapeutics kept more of each dollar of sales as profit: a net margin of 8.5% against -5.8%.
| Latest fiscal year | Eton PharmaceuticalsETON, 2025 | Gyre TherapeuticsGYRE, 2025 |
|---|---|---|
| Revenue | $80.0m | $117m |
| Revenue growth | 104.9% | 10.2% |
| Net income | −$4.6m | $9.9m |
| Operating margin | -1.1% | — |
| Net margin | -5.8% | 8.5% |
| Return on equity | -18.2% | 15.7% |
| Free cash flow | $10.2m | −$180,000 |
| Cash | $25.9m | $49.2m |
| Total debt | $30.6m | $0 |
| Debt to equity | 116.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 44 | — |
| Market value | $1.44bn | $472m |
| Price vs our value range | Above our value range | — |
| Moat score | 35 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 29 sales | 0 buys, 18 sales |